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CHARM = Candesartan in Heart Failure to Affect Reduction in Morbidity and Mortality; ELITE = Evaluation of Losartan in the Elderly; ELITE II =
Losartan Heart Failure Survival Study; ONTARGET = Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; OPTI-
MAAL = The Optimal Therapy in Myocardial Infarction with the AII Antagonist Losartan; Val-HeFT = Valsartan Heart Failure Trial; VALIANT = Valsar-
tan in Acute Myocardial Infarction Trial.
ACE = angiotensin-converting enzyme; CI = confidence interval; NYHA = New York Heart Association; RR = relative risk.
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Despite progress over recent decades in the prevention and
treatment of cardiovascular disease, heart failure continues to
place a significant and increasing burden on patients and
healthcare systems worldwide. In the USA alone, an esti-
mated four million to five million people suffer from chronic
heart failure, where it has an estimated five-year mortality rate
of 50% and is the leading cause of hospitalisation in age
groups 65 years and older [1,2].
Typically, a patient with heart failure has reduced cardiac
output, elevated filling pressures, and increased peripheral
vascular resistance. Heart failure is not a homogenous disease
process, however, and this makes the study of heart failure
potentially complex, and makes the comparison between dif-
ferent patient cohorts in different clinical trials difficult.
Angiotensin-converting enzyme (ACE) inhibitors are the treat-
ment of choice in heart failure, with proven ability to reduce
morbidity and mortality [3]. More recently, however, reporting
of data from large-scale clinical trials has focused attention
on the potential role of angiotensin II antagonists. Two such
trials — the Losartan Heart Failure Survival Study (ELITE II)
and the Valsartan Heart Failure Trial (Val-HeFT) — are
reviewed below.
ELITE II and Val-HeFT: similarities and
differences
Both ELITE II [4] and Val-HeFT [5] evaluated the efficacy of a
selective angiotensin II receptor antagonist on morbidity and
mortality in patients with symptomatic heart failure. There are
essential differences however, in the design of these trials
that must be taken into consideration when comparing these
two studies and interpreting the clinical impact of the results.
The bottom line, as detailed in this communication, is that the
trials address very different hypotheses and provide comple-
mentary but different types of information; too much compari-
son is simply inappropriate.
The hypotheses
The questions addressed reflect the most essential differ-
ences between the two trials. The primary hypothesis in the
ELITE II study was that losartan would be superior to capto-
Review
ELITE II and Val-HeFT are different trials: together what do they
tell us?
Kenneth Dickstein
University of Bergen, Cardiology Department, Central Hospital in Rogaland, Stavanger, 4011, Norway
Correspondence: Kenneth Dickstein, trout@online.no
Published online: 19 September 2001
Curr Control Trials Cardiovasc Med 2001, 2:240-243
© 2001 BioMed Central Ltd (Print ISSN 1468-6708; Online 1468-6694)
Abstract
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT)
both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity
and mortality in patients with symptomatic heart failure. The trials differed, however, in terms of their
primary hypothesis, study design, and treatment regimens, and this must be taken into consideration
when comparing and interpreting the data from these studies. The data are in many ways
complementary, and add to our understanding of the optimal treatment of symptomatic heart failure.
Additional studies are needed, however, to fully define the role of angiotensin II receptor antagonists in
the management of this very heterogeneous group of patients.

























pril with regard to survival. This was largely based on the
unexpectedly favourable results of the first Evaluation of
Losartan in the Elderly (ELITE) trial [6]. In ELITE II, the ACE
inhibitor captopril was again compared with the angiotensin II
antagonist, losartan, so there were two active arms. The study
had 90% power to detect a relative 25% difference in total
mortality between treatments.
In contrast, the primary hypothesis in Val-HeFT was that val-
sartan in addition to an ACE inhibitor would improve mortality
as compared to placebo (i.e. that the combination with an
angiotensin II antagonist would be better than an ACE
inhibitor alone). This study had 90% power to detect a rela-
tive 20% difference in total mortality between treatments.
Both trials were powered to detect superiority and were
event-driven; ELITE II required 510 deaths and Val-HeFT
required 906 deaths. ELITE II had a single primary endpoint:
all-cause mortality. Val-HeFT had two primary endpoints: all-
cause mortality and combined all-cause mortality/morbidity.
Morbidity was defined as death, sudden cardiac death with
resuscitation, hospitalisation for heart failure, or the need for
parenteral inotropic or vasodilator therapy.
Study designs
There were important differences with regard to the details of
study design. ELITE II randomised and titrated patients to a
relatively low dose of losartan (50 mg, once daily), or capto-
pril (50 mg, three times daily), in ACE-inhibitor-naïve patients.
Val-HeFT randomised and titrated patients to placebo or rela-
tively high doses of valsartan (160 mg, twice daily), in
patients tolerating chronic treatment with an ACE inhibitor.
Both trials included symptomatic patients in New York Heart
Association (NYHA) class II–IV, with an ejection fraction
<40% requiring therapy for heart failure. ELITE II, however,
restricted inclusion to patients >60 years old. Conventional
exclusion criteria were used in both trials. An ‘intention-to-
treat’ approach was utilised for the primary analysis of all effi-
cacy parameters in both trials. Both trials employed a Clinical
Endpoint Adjudication Committee.
Patient populations
The ELITE II trial included 3152 patients with a mean age of
71.4 years. Of these, 69% were male, the mean ejection frac-
tion for patients was 31%, 80% had a history of ischaemic
heart disease, 49% were in NYHA class II and 51% in NYHA
III/IV. Overall, 289 sites from 46 countries participated in the
ELITE II trial. The Val-HeFT study included 5009 patients with
a mean age of 62.7 years. Of these, 80% were male, the
mean ejection fraction for patients was 27%, 57% had a
history of ischaemic heart disease, 62% were in NYHA class
II and 38% in NYHA III/IV. In total, 300 sites from 16 coun-
tries participated in the Val-HeFT trial. Although the study
populations were similar in most respects, differences were
noted with regard to the number of patients treated with an
ACE inhibitor (ELITE II 23% [prior to randomisation],
Val-HeFT 92%) and with a beta-blocker (ELITE II 22%,
Val-HeFT 33%). In both ELITE II and Val-HeFT, patients were
stratified according to background beta-blocker therapy. Only
in the ELITE II protocol, however, was the proportion of ran-
domised patients taking beta-blockers limited to 25%
(although this was not reached in practice). Calculated annu-
alised mortality rates were 11% for ELITE II and 9% for
Val-HeFT.
Results
In the ELITE II trial, 79% of patients achieved the target dose
of test medication, compared with 80% in the Val-HeFT study.
The mean dose of losartan in ELITE II was 44 mg vs 254 mg
of valsartan in Val-HeFT. There were 530 deaths in ELITE II
and 906 deaths in Val-HeFT. Regarding all-cause mortality/all-
cause hospitalisation, there were a total of 1459 events in
ELITE II and a total of 1524 events in Val-HeFT. The median
follow up was 1.5 years in ELITE II and 1.9 years in Val-HeFT.
There were no significant differences between losartan and
captopril in ELITE II for either all-cause mortality or all-cause
hospitalisation, although there were, numerically, more deaths
in the losartan group. Although there was no significant differ-
ence in all-cause mortality in Val-HeFT, there was a significant
(13.3%) difference between valsartan and placebo in all-
cause mortality/morbidity in favour of valsartan (relative risk
[RR] 0.867, 95% confidence interval [CI] 0.784–0.959;
P = 0.009). This difference was almost completely due to a
27.5% reduction in all-cause hospitalisation in the valsartan
group (RR 0.725, 95% CI 0.630–0.833; P = 0.00001). Con-
sistent with the improvement in morbidity were significant
(P < 0.05) improvements in NYHA class, symptoms of heart
failure and quality-of-life assessments.
Subgroup analyses
Importantly, a subgroup of 366 (7%) patients included in the
Val-HeFT study was not treated with an ACE inhibitor. This
permits comparison between valsartan (as monotherapy) and
placebo. The results, albeit from a small subgroup of the study
population, indicate a highly statistically significant reduction
both in all-cause mortality (30% reduction, P = 0.01) and in
all-cause hospitalisation (44.5% reduction, RR 0.560, 95% CI
0.385 to 0.813; P = 0.0002). Exclusion of the subgroup of
patients not receiving an ACE-inhibitor therapy, makes the
observed overall reduction in the combined endpoint of mor-
tality and morbidity no longer significant.
Subgroup analysis in ELITE II does not suggest any signifi-
cant interactions between other concurrent therapy and the
effects of losartan or captopril. As stated in the results [4],
while there appeared to be an interaction with beta-blocker
usage at baseline, this difference was not seen if use was
based on concomitant treatment with beta-blockers during
the study. Patients on losartan or captopril who also took
beta-blockers did better than patients not on such treatment
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In the Val-HeFT study, in the subgroup (n = 1606; 32%)
treated with both an ACE inhibitor and a beta-blocker, a trend
favouring placebo was observed (risk increase 15% for val-
sartan versus placebo, RR 1.185, 95% CI 0.969–1.450). A
potential negative interaction in patients receiving an
angiotensin II antagonist in addition to both an ACE inhibitor
and a beta-blocker is biologically unexpected and this sub-
group finding should be viewed with caution. Further, this
issue is being adequately addressed by the large number of
patients receiving beta-blockers for secondary prophylaxis
following myocardial infarction, and randomised to the combi-
nation arm of valsartan plus captopril in the Valsartan in Acute
Myocardial Infarction Trial (VALIANT) [7].
Tolerability
Treatment with an angiotensin II antagonist was extraordinar-
ily well tolerated in both trials. In ELITE II, 14.5% of patients
on captopril, vs 9.4% on losartan,  discontinued taking the
study medication due to adverse experiences (P < 0.001). In
the Val-HeFT study, 9.9% of patients on valsartan, vs 7.2%
on placebo, discontinued taking the study medication due to
adverse experiences (P < 0.05). The data with valsartan are
particularly encouraging. The target dose in the Val-HeFT
study (320 mg) was reasonably high, and yet could still be
combined with an ACE inhibitor and tolerated well by
patients. Clearly, the two trials provide different information
with regard to tolerability. ELITE II compared losartan to cap-
topril in mainly ACE inhibitor naïve patients whereas Val-HeFT
compared valsartan to placebo in patients tolerating long-
term treatment with an ACE inhibitor.
Clinical implications
What are the major clinical implications of these two studies?
The results from the ELITE II trial suggest that treatment with
losartan (50 mg daily) is not superior to treatment with capto-
pril (50 mg three times daily) but is significantly better toler-
ated. Considering the extensive documentation confirming
the efficacy of ACE inhibitors in patients with heart failure [3],
these agents should remain the treatment of choice. Because
no significant differences regarding mortality or morbidity
were observed between losartan and captopril, losartan
would be an appropriate choice in patients intolerant of ACE
inhibitors.
The Val-HeFT study suggests that valsartan added to an ACE
inhibitor does not improve survival. Therapy with valsartan
added to an ACE inhibitor, however, did significantly reduce
hospitalisation in the entire cohort, so that the second primary
hypothesis (i.e. reduction in the combined endpoint of all-cause
mortality/morbidity) was supported. Importantly, valsartan
markedly improved survival and reduced hospitalisation in the
subgroup of patients who were not treated with an ACE
inhibitor. These findings in the subgroup without ACE inhibitor
treatment may well represent the strongest evidence to date
that angiotensin II antagonists are comparable in efficacy to
ACE inhibitors with regards to mortality and morbidity. Some
caution should be exercised when interpreting the data,
however, since a proportion of the patients enrolled in the Val-
HeFT study are likely to have been ACE-inhibitor intolerant and,
as such, may differ from the heart failure population in general.
The near future
There are currently three large ongoing trials in patients with
heart failure or left ventricular dysfunction (Table 1). These
studies, however, again address different hypotheses in
special populations and will not necessarily clearly define the
role of angiotensin II antagonists in the management of the
heterogeneous group of patients with chronic heart failure.
The Optimal Therapy in Myocardial Infarction with the AII
Antagonist Losartan (OPTIMAAL) study [8] compares losar-
tan to captopril in patients with left ventricular dysfunction fol-
lowing myocardial infarction (n = 5477), and is due to be
completed during the first quarter of 2002. VALIANT [7] com-
pares valsartan, captopril, and the combination (i.e. three
arms) in a similar population with left ventricular dysfunction
following myocardial infarction (n = 14,500), and the investi-
gators plan to report their findings in 2003. Both of these
post-infarction trials have prospectively included a noninferi-
ority hypothesis [9].
The Candesartan in Heart Failure to Affect Reduction in
Morbidity and Mortality (CHARM) study [10] is targeting
Table 1
Overview of ongoing angiotensin II antagonist trials in chronic heart failure (CHF) and post-myocardial infarction (post-MI)
patients
Study Patients Comparators Size Status
OPTIMAAL Post-MI Losartan vs captopril n = 5477 Recruitment complete; end date 2002
VALIANT Post-MI Valsartan vs captopril vs combination n = 14500 Recruitment complete; end date 2003
CHARM CHF Candesartan vs placebo n = 2548 Recruitment complete; end date 2003
CHF (ACE intolerant) Candesartan vs placebo n = 2028 Recruitment complete
Diastolic dysfunction Candesartan vs placebo n = 3024 Recruitment complete
ACE, angiotensin-converting enzyme.three different populations and compares candesartan to
placebo as add-on therapy in patients on chronic ACE
inhibitor therapy (arm 1, n = 2548), candesartan to placebo in
ACE inhibitor intolerant patients (arm 2, n = 2028), and also
candesartan to placebo in patients with symptomatic heart
failure and preserved systolic function (ejection fraction
>40%) (arm 3, n = 3024). CHARM will, therefore, provide
important information in three populations and will specifi-
cally, along with a more detailed analysis of Val-HeFT, deter-
mine the future role of combination therapy in clinical
research and practice.
A fourth trial — the Ongoing Telmisartan Alone and in Combi-
nation with Ramipril Global Endpoint Trial (ONTARGET) — is
also in progress (personal communication). This study, which
will compare an ACE inhibitor (ramipril) with an angiotensin II
antagonist (telmisartan), both alone and in combination, will
enrol an estimated 30,000 patients at high risk of cardiovas-
cular disease. It will not add to our understanding of treat-
ment options in heart failure, however, since patients with
symptomatic heart failure or decreased ejection fraction will
be excluded from the trial.
Investigators and clinicians involved in the management of
patients with heart failure must carefully digest the available
data in order to interpret better the results of the ongoing
trials. Selective angiotensin II receptor antagonists have a
multitude of theoretical benefits [11] and a side-effect profile
similar to placebo [12]. This makes their use attractive in this
syndrome in which therapy has become increasingly complex
and in which the target population is still inadequately treated
[13]. Their excellent tolerance would make angiotensin II
antagonists formidable contenders.
An unequivocal demonstration of efficacy comparable to ACE
inhibitors on both mortality and morbidity, however, is essential
if these agents are to attain first-line status. As placebo-
controlled trials without ACE inhibitors are clearly unethical,
the most appropriate way forward would appear to be a large,
three-arm trial powered to detect both superiority and equiva-
lence, comparing an ACE inhibitor vs an angiotensin II antago-
nist versus the combination on mortality and morbidity in
patients with heart failure. That would be ethical, feasible, and




1. American Heart Association: 2001 Heart and Stroke Statistical
Update. Dallas, TX: American Heart Association, 2001.
2. Graves EJ: National Hospital Discharge Survey: Annual
Summary, 1993: Vital and Health Statistics, Series 13. National
Health Survey 1995, 121:1-63.
3. Garg R, Yusuf S, for the collaborative group: Overview of ran-
domized trials of angiotensin converting enzyme inhibitors on
mortality and morbidity in patients with heart failure. JAMA
1995, 273:1450-1456.
4. Pitt S, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K,
Camm JA, Konstam MA, Riegger G, Klinger GH, Neaton J,
Sharma D, Thiyagarajan B: Randomised trial of losartan versus
captopril on mortality in patients with symptomatic heart
failure: the losartan heart failure survival study – ELITE II.
Lancet 2000, 355:1582-1587.
5. Cohn J, Tognoni G, Glazer R, Sporman D, Hester A: Rationale
and design of the Valsartan Heart Failure Trial: a large multi-
national trial to assess the effects of valsartan, an
angiotensin-receptor blocker, on morbidity and mortality in
chronic congestive heart failure. J Card Fail 1999, 5:155-160.
6. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I,
Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of
ELITE Study Investigators: Randomised trial of losartan versus
captopril in patients over 65 with heart failure. Lancet 1997,
349:747-752.
7. Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van
De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA,
Velazquez E, Califf R, for the VALIANT investigators: Valsartan in
acute myocardial infarction trial (VALIANT): rationale and
design. Am Heart J 2000, 140:727-734.
8. Dickstein K, Kjekshus J, for the OPTIMAAL Study Group: Com-
parison of the Effects of Losartan and Captopril on Mortality in
patients following Acute Myocardial Infarction: The OPTIMAAL
Trial Design. Am J Cardiol 1999, 83:477-481.
9. Snappin S: Noninferiority trials. Curr Controlled Trials Cardio-
vasc Med 2000, 1:19-22.
10. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G,
Olofsson B, Ostergren J, Yusuf S: Candesartan in heart failure –
assessment of reduction in mortality (CHARM): rationale and
design. J Card Fail 1999, 5:276-282.
11. Burnier M: Angiotensin II type 1 receptor blockers. Circulation
2001, 103:904-912.
12. Moore MA, Edelman JM, Gazdick LP, Vrecenak A, Delucca P, Fla-
herty JT, for the LET investigators: Choice of initial antihyperten-
sive medication may influence the extent to which patients
stay on therapy: a community-based study of a losartan-
based regimen vs usual care. High Blood Pressure 1998, 7:1-
12.
13. Hobbs FDR, Jones MI, Allan TF, Wilson S, Tobias R: European
survey of primary care physician perceptions on heart failure
diagnosis and management (Euro-HF). Eur Heart J 2000,
21:1877-1887.
Available online http://cvm.controlled-trials.com/content/2/5/240
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
s
e
a
r
c
h